118
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Marine Polysaccharides: A Source of Bioactive Molecules for Cell Therapy and Tissue Engineering

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The therapeutic potential of natural bioactive compounds such as polysaccharides, especially glycosaminoglycans, is now well documented, and this activity combined with natural biodiversity will allow the development of a new generation of therapeutics. Advances in our understanding of the biosynthesis, structure and function of complex glycans from mammalian origin have shown the crucial role of this class of molecules to modulate disease processes and the importance of a deeper knowledge of structure-activity relationships. Marine environment offers a tremendous biodiversity and original polysaccharides have been discovered presenting a great chemical diversity that is largely species specific. The study of the biological properties of the polysaccharides from marine eukaryotes and marine prokaryotes revealed that the polysaccharides from the marine environment could provide a valid alternative to traditional polysaccharides such as glycosaminoglycans. Marine polysaccharides present a real potential for natural product drug discovery and for the delivery of new marine derived products for therapeutic applications.

          Related collections

          Most cited references83

          • Record: found
          • Abstract: found
          • Article: not found

          The structure of glycosaminoglycans and their interactions with proteins.

          Glycosaminoglycans (GAGs) are important complex carbohydrates that participate in many biological processes through the regulation of their various protein partners. Biochemical, structural biology and molecular modelling approaches have assisted in understanding the molecular basis of such interactions, creating an opportunity to capitalize on the large structural diversity of GAGs in the discovery of new drugs. The complexity of GAG-protein interactions is in part due to the conformational flexibility and underlying sulphation patterns of GAGs, the role of metal ions and the effect of pH on the affinity of binding. Current understanding of the structure of GAGs and their interactions with proteins is here reviewed: the basic structures and functions of GAGs and their proteoglycans, their clinical significance, the three-dimensional features of GAGs, their interactions with proteins and the molecular modelling of heparin binding sites and GAG-protein interactions. This review focuses on some key aspects of GAG structure-function relationships using classical examples that illustrate the specificity of GAG-protein interactions, such as growth factors, anti-thrombin, cytokines and cell adhesion molecules. New approaches to the development of GAG mimetics as possible new glycotherapeutics are also briefly covered.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Matrix proteoglycans: from molecular design to cellular function.

            R Iozzo (1998)
            The proteoglycan superfamily now contains more than 30 full-time molecules that fulfill a variety of biological functions. Proteoglycans act as tissue organizers, influence cell growth and the maturation of specialized tissues, play a role as biological filters and modulate growth-factor activities, regulate collagen fibrillogenesis and skin tensile strength, affect tumor cell growth and invasion, and influence corneal transparency and neurite outgrowth. Additional roles, derived from studies of mutant animals, indicate that certain proteoglycans are essential to life whereas others might be redundant. The review focuses on the most recent genetic and molecular biological studies of the matrix proteoglycans, broadly defined as proteoglycans secreted into the pericellular matrix. Special emphasis is placed on the molecular organization of the protein core, the utilization of protein modules, the gene structure and transcriptional control, and the functional roles of the various proteoglycans. When possible, proteoglycans have been grouped into distinct gene families and subfamilies offering a simplified nomenclature based on their protein core design. The structure-function relationship of some paradigmatic proteoglycans is discussed in depth and novel aspects of their biology are examined.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              From carbohydrate leads to glycomimetic drugs

              Key Points Carbohydrates coat the surfaces of all cells and most proteins. They contain molecular information used in recognition events with carbohydrate-binding proteins (such as the lectin families) that decode this information. These bioactive carbohydrates open up a new source of novel targets for drug development. Although carbohydrates have prominent roles in a wide range of biological processes, the currently approved drugs are mainly glycosidase inhibitors and sulphated glycosaminoglycans (that is, heparin). Current preclinical research on lectins that are found in humans and pathogens indicates that glycomimetics could provide an alternative strategy for the treatment of inflammatory diseases (by targeting selectins) and infectious diseases (by targeting dendritic cell-specific ICAM3-grabbing non-integrin 1 (DC-SIGN), FimH, PA-I galactophilic lectin (PA-IL) and fructose-binding PA-IIL lectins). In general, carbohydrates lack drug-like properties such as high affinity or adequate bioavailability and therapeutically relevant plasma half-lives. In addition, their large-scale production is cumbersome and expensive. When developing this class of drugs, the goal is to mimic the biological information of a functional carbohydrate with a glycomimetic that overcomes these challenges and has appropriate pharmacodynamic and pharmacokinetic properties.
                Bookmark

                Author and article information

                Journal
                Mar Drugs
                MD
                Marine Drugs
                Molecular Diversity Preservation International
                1660-3397
                2011
                23 September 2011
                : 9
                : 9
                : 1664-1681
                Affiliations
                [1 ] Seadev-FermenSys SAS, Technopole Brest Iroise, 185 rue René Descartes, Plouzané 29280, France; E-Mail: senni@ 123456seadev.fr
                [2 ] INSERM U765, Faculté de Pharmacie, UMR-S765, Université Paris Descartes, Sorbonne Paris Cité, 4 avenue de l’Observatoire, Paris 75006, France; E-Mails: jessica.pereira@ 123456etu.parisdescartes.fr (J.P.); anne-marie.fischer@ 123456egp.aphp.fr (A.-M.F.); dominique.helley@ 123456egp.aphp.fr (D.H.)
                [3 ] Biochemistry Department, Faculty of Dental Surgery, Paris Descartes University, Montrouge 92120, France; E-Mails: gueniche_farida@ 123456yahoo.fr (F.G.); godeau_g@ 123456yahoo.fr (G.G.)
                [4 ] Laboratory of Biotechnology and Marine Molecules, Ifremer, Rue de l’Ile d’Yeu, BP 21105, Nantes Cedex 03 44311, France; E-Mails: Christine.Delbarre.Ladrat@ 123456ifremer.fr (C.D.-L.); Corinne.Sinquin@ 123456ifremer.fr (C.S.); Jacqueline.Ratiskol@ 123456ifremer.fr (J.R.)
                [5 ] AP-HP, Biological Hematology Department, European Hospital Georges Pompidou, 20 rue Leblanc, Paris 75015, France
                Author notes
                [* ] Author to whom correspondence should be addressed; E-Mail: Sylvia.Colliec.Jouault@ 123456ifremer.fr ; Tel.: +33-2-4037-4093; Fax: +33-2-4037-4071.
                [†]

                These authors contributed equally to this work.

                Article
                marinedrugs-09-01664
                10.3390/md9091664
                3225941
                22131964
                4f588c61-7569-44c1-83e8-cff52ae9c39f
                © 2011 by the authors; licensee MDPI, Basel, Switzerland

                This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license ( http://creativecommons.org/licenses/by/3.0/).

                History
                : 22 July 2011
                : 02 September 2011
                : 05 September 2011
                Categories
                Review

                Pharmacology & Pharmaceutical medicine
                blue biotechnology,tissue engineering,cell therapy,structure,marine algae,exopolysaccharides,sulfated polysaccharides,biological activity,marine bacteria,chemical modification

                Comments

                Comment on this article